The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.
 
Sophia Frentzas
No Relationships to Disclose
 
Tarek Meniawy
Honoraria - AstraZeneca/MedImmune
Consulting or Advisory Role - AstraZeneca/MedImmune
Research Funding - AstraZeneca/MedImmune (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Incyte (Inst); Merck Serono (Inst); Regeneron (Inst); Roche/Genentech (Inst)
Travel, Accommodations, Expenses - Roche/Genentech
 
Steven Chuan-Hao Kao
Honoraria - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
Research Funding - AstraZeneca (Inst)
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Roche
 
Ruihua Wang
Employment - BeiGene
 
Yunxia Zuo
Employment - BeiGene; BeiGene (I); Hengrui Medicine; Hengrui Medicine (I)
Stock and Other Ownership Interests - BeiGene
Travel, Accommodations, Expenses - BeiGene; BeiGene (I); Hengrui Medicine; Hengrui Medicine (I)
 
Hao Zheng
Employment - BeiGene; Gilead Sciences
Stock and Other Ownership Interests - BeiGene; Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
Wei Tan
Employment - BeiGene
Stock and Other Ownership Interests - BeiGene